cirrhosis
Akero Therapeutics’ shares plummet after phase 2b trial of NASH drug fails to improve cirrhosis
Anika Sharma
Akero Therapeutics, a leading contender in the nonalcoholic steatohepatitis (NASH) field, has encountered a setback as its FGF21 analog, efruxifermin ...
